Peptide imaging agent developer Diatide of Londonderry, NH, planson issuing an initial public offering in the next several weeksthat will raise $25 million to fund ongoing product development.The firm will price its stock at $10 to $12 a share,
Peptide imaging agent developer Diatide of Londonderry, NH, plans
on issuing an initial public offering in the next several weeks
that will raise $25 million to fund ongoing product development.
The firm will price its stock at $10 to $12 a share, according
to president Richard Dean. Diatide's lead product is a technetium-99m-labeled
agent for detection of deep vein thrombosis.